Abliva AB

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 16:29:40 28/05/2024 BST			5-day change	1st Jan Change
0.1832 ^SEK	-2.03%		-4.68%	-25.38%

05-23	Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-21	Transcript : Abliva AB - Special Call

NeuroVive Pharmaceutical AB will Change its Name to Abliva AB

May 27, 2020 at 05:00 am

Effective May 27, 2020, NeuroVive Pharmaceutical AB will change its name to Abliva AB.

Latest news about Abliva AB

Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Transcript : Abliva AB - Special Call	05-21
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-23	CI
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	12-20	CI
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps	12-14	MT
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury	11-14	CI
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study	11/10/23	CI
Abliva Rises 28% on US FDA Fast Track Designation for Mitochondrial Disease Drug Candidate	04/09/23	MT
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/08/23	CI
Abliva AB Announces First Patient Dosed in the Falcon Study	28/06/23	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/05/23	CI
Abliva AB Announces Resignation of Edwin Moses as Director	04/05/23	CI
Abliva Up 15% on US FDA's Orphan Designation for Mitochondrial Disease Treatment Candidate	17/04/23	MT
Abliva AB Elects Edwin Moses as New Board Member	08/03/23	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	24/02/23	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2022	24/02/23	CI
Certain Shares of Abliva AB are subject to a Lock-Up Agreement Ending on 28-DEC-2022.	27/12/22	CI
Abliva Starts Mid-stage Study Of Rare Metabolical Disease Drug	06/12/22	MT
Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333	06/12/22	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/11/22	CI
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/08/22	CI
Transcript : Abliva AB - Special Call	01/06/22
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2022	31/05/22	CI
Abliva AB Auditor Raises 'Going Concern' Doubt	28/04/22	CI

Chart Abliva AB

Duration

Period

More charts

Company Profile

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABLIVA AB	-25.38%	23.78M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs

Abliva AB

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

NeuroVive Pharmaceutical AB will Change its Name to Abliva AB

Latest news about Abliva AB

Chart Abliva AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs